GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Gland Pharma Ltd
Gland Pharma Board Reappoints Independent Director for 5 Years
BOARD ● No Immediate Change LOW RISK
📅 Filed on BSE: 15 Jun 2026, 04:42 PM IST  ·  BSE ID: 3712bc65-44d4-4d19-a3aa-e84ae601715a
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board has decided to keep an existing independent director for another five years, subject to shareholder approval.
🤖 AI Summary
  • Board reappointed Mr. Uddo Johannes Vetter as Independent Director.
  • Second term of five consecutive years approved.
  • Reappointment effective July 21, 2026, through July 20, 2031.
  • Shareholder approval required per listing regulations.
  • Meeting held on June 15, 2026, in compliance with SEBI rules.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Term Start Date
July 21, 2026
Term End Date
July 20, 2031
Director's DIN
00070744
🏢 How This Affects the Company
⚙️
Operational Impact
The continuation of an independent director suggests stability in corporate governance oversight, which can indirectly support long-term strategic decision-making.
⚠️
Risk Impact
Reappointment of an experienced independent director may help mitigate governance-related risks by ensuring continued adherence to regulatory compliance and best practices.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to vote on the reappointment of Mr. Uddo Johannes Vetter at the upcoming annual general meeting.
👤
Who Is Affected
All shareholders of Gland Pharma Limited are affected as they will participate in the voting process to approve the director's reappointment.
🔍
Management Signal
This decision signals management's confidence in the incumbent independent director's contribution and commitment to maintaining corporate governance continuity.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Outcome of shareholder voting on director reappointment.
Notice of the Annual General Meeting for shareholder voting.
Confirmation of the new director term officially commencing.
LOW RISK Routine board decision on director reappointment, pending shareholder approval.
💡 Investor Takeaway
Gland Pharma's board has approved a five-year reappointment for an Independent Director, effective July 21, 2026. Shareholder approval is pending for this decision made on June 15, 2026.
❓ Frequently Asked Questions
Who was reappointed as an Independent Director at Gland Pharma?
Mr. Uddo Johannes Vetter was reappointed as an Independent Director for a second term.
What is the duration of the reappointment for Mr. Uddo Johannes Vetter?
The reappointment is for a second term of five consecutive years, from July 21, 2026, to July 20, 2031.
When was the Gland Pharma Board Meeting held to approve the reappointment?
The Board Meeting of Gland Pharma Limited was held on Monday, June 15, 2026, to consider and approve the reappointment.
Does the reappointment of the Independent Director require shareholder approval?
Yes, the approval of the members is required under Regulation 17(1A) and 25(2A) of the Listing Regulations for this reappointment.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.